Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
This is a multicenter, Phase 2a, open-label, 2-part study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) in combination with palbociclib plus fulvestrant. Eligible patients include those with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-positive breast cancer.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
Part 1 of the study will first evaluate the safety and tolerability of ZW25 in combination with palbociclib plus fulvestrant and will confirm the recommended doses (RDs) of ZW25 and palbociclib in this combination. Part 2 of the study will evaluate the anti-tumor activity of the combination of ZW25 with palbociclib plus fulvestrant at the RD level in patients with HER2-positive, HR-positive advanced breast cancer.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N4N2
- Tom Baker Cancer Centre
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1H 8L6
- The Ottawa Hospital Cancer Centre
-
Toronto, Ontario, Kanada, M4N3M5
- Sunnybrook Research Institute
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T1E2
- Jewish General Hospital
-
-
-
-
California
-
Santa Monica, California, Spojené státy, 90404
- UCLA Hematology/Oncology Parkside
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37203
- Sarah Cannon Research Institute
-
-
Washington
-
Seattle, Washington, Spojené státy, 98109
- Seattle Cancer Care Alliance
-
-
-
-
-
Barcelona, Španělsko, 08035
- Hospital Universitario Vall d'Hebrón
-
Madrid, Španělsko, 28034
- Hospital Ruber Internacional
-
Málaga, Španělsko, 29010
- Hospital Universitario Virgen de la Victoria
-
Seville, Španělsko, 41013
- Hospital Universitario Virgen del Rocío
-
Valencia, Španělsko, 46010
- Hospital Clínico Universitario de Valencia
-
-
Alicante
-
Elche, Alicante, Španělsko, 03203
- Hospital General Universitario de Elche
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Pathologically-confirmed diagnosis of breast cancer with evidence of locally advanced (unresectable) and/or metastatic disease. All patients in both Parts 1 and 2 must have HER2-positive and HR-positive disease.
- Received prior treatment with trastuzumab, pertuzumab, AND ado-trastuzumab emtansine (T-DM1); disease progression during or after the most recent prior therapy. Patients in any part of the study who did not receive pertuzumab or T-DM1 because of lack of access (e.g., due to insurance coverage or because they were treated prior to regulatory agency approval of the agent in a relevant indication) or due to medical ineligibility for treatment with T-DM1 (e.g., history of severe infusion reactions to trastuzumab, >/= Grade 2 peripheral neuropathy, or platelet count < 100 x 10^9/L) may be eligible for the study. Prior treatment with endocrine therapy in the neoadjuvant, adjuvant, and/or metastatic setting is permitted.
- Sites of disease assessible per RECIST version 1.1 (both measurable and non-measurable disease allowed)
- An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Adequate organ function
- Adequate cardiac left ventricular function, as defined by left ventricular ejection fraction (LVEF) >/= institutional standard of normal
Exclusion Criteria:
- Prior treatment with trastuzumab, pertuzumab, lapatinib, T-DM1, or other anti-HER2-targeted therapy </= 3 weeks before the first dose of ZW25
- Prior treatment with chemotherapy, other anti-cancer therapy not otherwise specified, or hormonal cancer therapy </= 3 weeks before the first dose of ZW25
- Prior treatment with palbociclib or any other CDK4/6 inhibitor, including experimental agents
- History of myocardial infarction or unstable angina within 6 months prior to enrollment, troponin levels consistent with myocardial infarction, or clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension, or any history of symptomatic congestive heart failure (CHF)
- QTc Fridericia (QTcF) > 470 ms
- Grade 2 or greater pneumonitis and/or interstitial lung disease, including pulmonary fibrosis, or other clinically significant infiltrative pulmonary disease not related to lung metastases
- Active hepatitis B or hepatitis C infection
- Acute or chronic uncontrolled renal disease, pancreatitis, or severe liver disease (Child-Pugh Class C)
- Known infection with Human Immunodeficiency Virus (HIV)-1 or HIV-2 (Exception: patients with well controlled-HIV [e.g., cluster of differentiation 4 (CD4)-positive T-cell count > 350 mm3 and undetectable viral load] are eligible.)
- Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
- Brain metastases: Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks of start of study treatment. Stable, treated brain metastases are allowed (defined as patients who are off steroids and anticonvulsants and are neurologically stable for at least 1 month at the time of screening).
- History of or ongoing leptomeningeal disease
- Grade 3 or greater peripheral neuropathy
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Sekvenční přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: ZW25 (zanidatamab) + palbociclib + fulvestrant
Participants who received intravenous dose of 20 mg/kg ZW25 (zanidatamab) every 2 weeks (Q2W) in combination with an oral administration of 125 mg palbociclib once daily from Days 1 to 21, and an intramuscular injection of 500 mg fulvestrant Q2W for 3 doses (Cycle 1 Days 1 and 15 and Cycle 2 Day 1), and every 4 weeks (Q4W) thereafter. |
Administered orally Administered intravenously Administered as an intramuscular injection |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants With Dose-Limiting Toxicities
Časové okno: Cycle 1 Day 1 to Day 28 (each cycle is 28 days)
|
Dose-limiting toxicities, defined using NCI CTCAE version 5.0, are events that 1) occur following administration of ZW25, palbociclib, and fulvestrant; and 2) meet the criteria as specified in the protocol. |
Cycle 1 Day 1 to Day 28 (each cycle is 28 days)
|
|
Number of Participants Reporting Grade 3 or Higher Treatment-emergent Adverse Events
Časové okno: From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days.
|
A treatment-emergent adverse event occurs after the start of study treatment and is defined as any unfavorable or unintended symptom, sign, or disease (including abnormal lab) temporally associated with the use of treatment that may or may not be considered related to treatment. TEAEs were coded using MedDRA v24.0. |
From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days.
|
|
Progression-free Survival 6
Časové okno: 6 months from first dose of all study drugs to the date of documented disease progression or death
|
The progression-free survival at 6 months (PFS6) is a binary endpoint variable based on the progression-free survival (PFS) time, defined as the proportion of participants having PFS time greater than or equal to 24 weeks (168 days). |
6 months from first dose of all study drugs to the date of documented disease progression or death
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants Reporting Any Treatment-emergent Adverse Event, Serious Adverse Event, and Adverse Event of Special Interest
Časové okno: From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days
|
A treatment-emergent adverse events (TEAEs) was defined as an adverse event (AE) with onset on or after 1st dose of study treatment through 30 days after final dose of study treatment inclusive. An AE is classified as a serious adverse event (SAE) if fatal, life threatening, requires hospitalization, is disabling/incapacitating, causes congenital anomaly or birth defect, and medically significant. Adverse events of special interest (AESI) include absolute decrease in LVEF greater than or equal to 10 percentage points from baseline and LVEF value less than 50% post-baseline or LVEF value greater than or equal to 20% to less than or equal to 39% post baseline, symptomatic heart failure, infusion-related reactions, and all greater than or equal to Grade 2 events of pneumonitis and/or interstitial lung disease, including pulmonary fibrosis. |
From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days
|
|
Maximum Serum Concentration Steady State of ZW25
Časové okno: End of ZW25 infusion on Cycle 4 Day 1 (steady state) (each cycle is 28 days)
|
Pharmacokinetics (PK) were evaluated using noncompartmental analysis (NCA). |
End of ZW25 infusion on Cycle 4 Day 1 (steady state) (each cycle is 28 days)
|
|
Trough Concentration Steady State of ZW25
Časové okno: Predose at Cycle 4 Day 1 (steady state) (each cycle is 28 days)
|
Pharmacokinetics (PK) were evaluated using noncompartmental analysis (NCA). |
Predose at Cycle 4 Day 1 (steady state) (each cycle is 28 days)
|
|
Number of Participants With Anti-drug Antibodies (ADAs) Post-baseline
Časové okno: Predose at Cycle 1 Days 1 and 15; Cycle 2 Days 1 and 15; Cycle 4 Day 1 and subsequent ADA assessment visits; end of treatment; 30 days post last dose (safety FU); and every 8 weeks (efficacy FU) (each cycle, 28 days), up to approximately 5 years 20 days.
|
Participants were considered to be ADA positive if they were initially ADA negative at baseline and tested positive for ADAs following study drug exposure ("treatment-induced ADA response"), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 4-fold greater than the titer of the baseline sample ("treatment-enhanced ADA response"). Participants were considered to be ADA negative if they were ADA negative at baseline and all post-baseline samples were negative, or if they were ADA positive at baseline but did not have any post-baseline samples with a titer that was at least 4-fold greater than the titer of the baseline sample ("treatment-unaffected ADA"). |
Predose at Cycle 1 Days 1 and 15; Cycle 2 Days 1 and 15; Cycle 4 Day 1 and subsequent ADA assessment visits; end of treatment; 30 days post last dose (safety FU); and every 8 weeks (efficacy FU) (each cycle, 28 days), up to approximately 5 years 20 days.
|
|
Objective Response Rate
Časové okno: From first dose of treatment up to end of study, approximately 5 years 20 days
|
Confirmed objective response rate is defined as the number of patients with confirmed complete response (CR) and confirmed partial response (PR). CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions as assessed by the Investigator per RECIST v1.1. |
From first dose of treatment up to end of study, approximately 5 years 20 days
|
|
Duration of Response
Časové okno: From first dose of treatment up to end of study, approximately 5 years 20 days
|
DOR is defined as the time from the first confirmed objective response (CR or PR) to documented PD per RECIST 1.1 or death within 30 days of last dose of study drug (ZW25, palbociclib, and/or fulvestrant) from any cause. Only participants who achieved a confirmed objective response were included in the analysis. |
From first dose of treatment up to end of study, approximately 5 years 20 days
|
|
Disease Control Rate
Časové okno: From first dose of treatment up to end of study, approximately 5 years 20 days
|
Disease control is defined as a best response of CR, PR, non-CR/non-PD (for participants who have only non-target lesions), or SD per RECIST 1.1. The proportion of participants who achieve a disease control response was calculated. |
From first dose of treatment up to end of study, approximately 5 years 20 days
|
|
Progression-free Survival
Časové okno: From first dose of treatment up to end of study, approximately 5 years 20 days
|
Progression-free survival (PFS) time is defined as the time from first dose of ZW25, palbociclib, and/or fulvestrant to the date of first documented disease progression (per RECIST 1.1) or death from any cause, whichever occurs first. |
From first dose of treatment up to end of study, approximately 5 years 20 days
|
|
Overall Survival
Časové okno: From first dose of treatment up to end of study, approximately 5 years 20 days
|
OS is defined as time from first dose of ZW25, palbociclib, and/or fulvestrant until death from any cause. |
From first dose of treatment up to end of study, approximately 5 years 20 days
|
|
Incidence of Abnormal Hepatic Lab Values
Časové okno: From first dose of treatment up to end of study, approximately 5 years 20 days
|
From first dose of treatment up to end of study, approximately 5 years 20 days
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Novotvary podle místa
- Novotvary
- Kožní choroby
- Nemoci prsu
- Onemocnění kůže a pojivové tkáně
- Novotvary prsu
- Hormony
- Hormony, hormonální náhražky a antagonisté hormonů
- Polycyklické sloučeniny
- Steroidy
- Sloučeniny roztaveného kruhu
- Estradiol
- Estreny
- Estranes
- Estradiolové kongenery
- Gonadal steroidní hormony
- Gonadální hormony
- Fulvestrant
- Palbociclib
- zanidatamab
Další identifikační čísla studie
Další identifikační čísla studie
- ZWI-ZW25-202
- 2019-002956-18 (Číslo EudraCT)
- 2019 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .